Table 2 Autophagy-related markers in combination hepatocellular carcinoma and cholangiocarcinoma
Total (n = 40) | Non-mortality (n = 25) | Mortality (n = 15) | P-value | Non-recurrence | Recurrence | P-value | |
|---|---|---|---|---|---|---|---|
LC3 in tumors | |||||||
Low | 7 (17.5) | 1 (4.0) | 6 (40.0) | 0.004 | 2 (6.7) | 5 (50.0) | 0.002 |
High | 33 (82.5) | 24 (96.0) | 9 (60.0) | 28 (93.3) | 5 (50.0) | ||
Beclin-1 in tumors | |||||||
Low | 15 (37.5) | 7 (28.0) | 8 (53.3) | 0.109 | 9 (30.0) | 6 (60.0) | 0.09 |
High | 25 (62.5) | 18 (72.0) | 7 (46.7) | 21 (70.0) | 4 (40.0) | ||
p62 in tumors | |||||||
Low | 13 (32.5) | 10 (40.0) | 3 (20.0) | 0.191 | 21 (70.0) | 8 (80.0) | 0.54 |
High | 27 (76.5) | 15 (60.0) | 12 (80.0) | 9 (30.0) | 2 (20.0) | ||
LC3 in ANT | |||||||
Low | 15 (37.5) | 9 (36.0) | 6 (40.0) | 0.8 | 10 (33.3) | 5 (50.0) | 0.346 |
High | 25 (62.5) | 16 (64.0) | 9 (60.0) | 20 (66.7) | 5 (50.0) | ||
Beclin-1 in ANT | |||||||
Low | 17 (42.5) | 10 (40.0) | 7 (46.7) | 0.68 | 11 (36.7) | 6 (60.0) | 0.196 |
High | 23 (57.5) | 15 (60.0) | 8 (53.3) | 19 (63.3) | 4 (40.0) | ||
p62 in ANT | |||||||
Low | 24 (60.0) | 15 (60.0) | 9 (60.0) | 0.99 | 20 (66.7) | 4 (40.0) | 0.136 |
High | 16 (40.0) | 10 (40.0) | 6 (40.0) | 10 (33.3) | 6 (60.0) | ||